LEAMINGTON, ON, April 18, 2019 /PRNewswire/ - Aphria Inc.
("Aphria" or the "Company") (TSX: APHA and NYSE:
APHA) today announced that its German subsidiary Aphria Deutschland
GmbH ("Aphria Germany") has secured the previously announced
license for the domestic cultivation of medical cannabis from the
German Federal Institute for Drugs and Medical Devices
("BfArM"), following the conclusion of a mandatory 10-day
standstill period for public contracts. Aphria was granted a
cultivation license for four of the nine total lots awarded by
BfArM and is awaiting the completion of the tender process for the
four remaining lots under review, one of which was provisionally
awarded to Aphria Germany.
"Aphria thanks the BfArM for their diligent examination and
validation of our approach for domestic cultivation with this
license," said Hendrik Knopp,
Managing Director of Aphria Germany. "Construction on our 8,000
square meter indoor cultivation facility is already underway and we
anticipate it will be fully operational by Summer 2020. We are
pleased to additionally support German patients in the upcoming
months with high-quality imported cannabis flower and oils from
Denmark and Canada."
Aphria Germany is building its indoor growing facility in
Neumünster and is completing work on a state-of-the-art
GMP-certified cannabis vault in Bad Bramstedt for the import
of cannabis flowers and oil from Canada and Denmark. Aphria Germany also holds a 25.1%
interest in Berlin-based
Schöneberg Hospital, which provides access to both doctors and
patients for education on the benefits of medical cannabinoids.
Earlier this month, the company launched CannRelief, a CBD-based
nutraceutical and cosmetics product line for the German market,
produced in the EU and distributed by CC Pharma, a subsidiary of
Aphria Inc. with access to more than 13,000 pharmacies throughout
Germany.
We Have A Good Thing Growing
About Aphria
Aphria is a leading global cannabis
company driven by an unrelenting commitment to our people, the
planet, product quality and innovation. Headquartered in
Leamington, Ontario – the
greenhouse capital of Canada –
Aphria has been setting the standard for the low-cost production of
high-quality cannabis at scale, grown in the most natural
conditions possible. Focusing on untapped opportunities and backed
by the latest technologies, Aphria is committed to bringing
breakthrough innovation to the global cannabis market. The
Company's portfolio of brands is grounded in expertly-researched
consumer insights designed to meet the needs of every consumer
segment. Rooted in our founders' multi-generational expertise in
commercial agriculture, Aphria drives sustainable long-term
shareholder value through a diversified approach to innovation,
strategic partnerships and global expansion, with a presence in
more than 10 countries across 5 continents.
For more information, visit: aphria.ca
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to internal expectations,
estimated margins, expectations with respect to actual production
volumes, expectations for future growing capacity and costs, the
completion of any capital project or expansions, and expectations
with respect to future production costs. Forward-looking statements
necessarily involve known and unknown risks, including, without
limitation, risks associated with delays in construction,
materials, and reliance on contractors, building permits and the
like; general economic conditions; adverse industry events;
marketing costs; loss of markets; future legislative and regulatory
developments involving cannabis; inability to access sufficient
capital from internal and external sources, and/or inability to
access sufficient capital on favourable terms; the cannabis
industry in Canada generally,
income tax and regulatory matters; the ability of Aphria to
implement its business strategies; competition; crop failure;
currency and interest rate fluctuations and other risks.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
View original
content:http://www.prnewswire.com/news-releases/aphria-secures-cannabis-cultivation-license-in-germany-300834959.html
SOURCE Aphria Inc.